Neonatal thrombocytosis resulting from the maternal use of non-narcotic antischizophrenic drugs during pregnancy

Y Nako, A Tachibana, T Fujiu, T Tomomasa, A Morikawa

Abstract
Neonatal thrombocytosis can result from maternal narcotic drug abuse. The case of a male infant is reported who was born to a woman with schizophrenia treated with non-narcotic psychotropic drugs during pregnancy; he developed severe prolonged thrombocytosis. The platelet count reached 1310 × 10^9/l on day 15. This thrombocytosis persisted for three months. The patient was treated with dipyridamole. A bone marrow aspirate showed normal myeloid and erythroid precursors with an increased number of megakaryocytes. Plasma concentrations of interleukin 6 and thrombopoietin were suppressed. No obvious complications from the thrombocytosis occurred, and the platelet count fell to within the upper limit of normal after 3 months of age. This case indicates that thrombocytosis may occur in infants born to mothers treated with non-narcotic psychopharmaceutical drugs during pregnancy. The thrombocytosis in this case may have been induced by factors other than interleukin 6 or thrombopoietin.

Keywords: neonatal drug withdrawal syndrome; psychopharmaceuticals; thrombocytosis; thrombopoietin

Case report
A male infant was delivered vaginally after 35 weeks and five days of gestation. His 25 year old Japanese mother, 0 para 0 gravida, had been diagnosed as having schizophrenia at 23 years of age. She had been treated with psychopharmaceutical drugs (haloperidol 12 mg/day, biperiden 5 mg/day, promethazine hydrochloride 25 mg/day, nitrazepam 5 mg/day, chlorpromazine 50 mg/day) until the day of delivery. She was not taking opiate illicitly. The pregnancy and delivery were uneventful.

At admission, blood studies were unremarkable. Blood platelet count at birth was 402 × 10^9/l. For evaluation of possible neonatal drug withdrawal syndrome, we used a scoring system proposed by the Japanese Welfare Ministry and adapted from Finningan et al. The score for severity of the syndrome peaked at 7 days of age and totalled 7 points, based on decreased muscle tone (1 point), tremor on stimulation (2 points), vomiting (2 points), and poor feeding (2 points). The severity decreased gradually, reaching a score of 0 by day 12 without any medication. The baby was fed a regular formula.

The patient’s platelet count initially fell to 117 × 10^9/l on day 6 but increased thereafter from 832 × 10^9/l on day 8 to a maximum of 1310 × 10^9/l on day 15. The result of a platelet adhesion test was 98.8% (normal range in our laboratory 20–60%) on day 15. Therefore, treatment with dipyridamole (2 mg/kg/day) was started on day 15 for prevention of thrombotic complications. A bone marrow aspirate on day 31 of age showed normal myeloid and erythroid precursors with an increased number of megakaryocytes: total cell count, 168 333/µl; megakaryocyte count, 198/µl (0.12%; the normal range is 79.9–269.8/µl); and serum thrombopoietin concentration was not increased (15.0 mU/ml). Blood thrombopoietin concentration, measured by a sensitive enzyme linked immunosorbent assay, and interleukin 6 (IL6) concentrations, measured by chemiluminescent enzyme immunoassay, were not elevated, but rather depressed; plasma thrombopoietin concentration ranged from 7 to 63.1 pg/ml (the normal range is 79.9–269.8 pg/ml at 1 month and 36.9–150.5 pg/ml at 2–11 months), and serum IL6 concentrations ranged from 0.3 to 5.2 pg/ml (the normal range is 2.4–10.5 pg/ml at day 5 and 0.7–11 pg/ml at day 40). Serum C reactive protein concentrations were < 0.1 mg/dl. After the platelet count decreased to 820 × 10^9/l on day 91, dipyridamole was stopped. Thereafter, the platelet count decreased further to 600 × 10^9/l. However, it remained relatively high, over 400 × 10^9/l after 4 months of age (fig 1). The infant had no symptoms attributable to thrombocytosis.

Keywords: neonatal drug withdrawal syndrome; psychopharmaceuticals; thrombocytosis; thrombopoietin

Case report
A male infant was delivered vaginally after 35 weeks and five days of gestation. His 25 year old Japanese mother, 0 para 0 gravida, had been diagnosed as having schizophrenia at 23 years of age. She had been treated with psychopharmaceutical drugs (haloperidol 12 mg/day, biperiden 5 mg/day, promethazine hydrochloride 25 mg/day, nitrazepam 5 mg/day, chlorpromazine 50 mg/day) until the day of delivery. She was not taking opiate illicitly. The pregnancy and delivery were uneventful.

At admission, blood studies were unremarkable. Blood platelet count at birth was 402 × 10^9/l. For evaluation of possible neonatal drug withdrawal syndrome, we used a scoring system proposed by the Japanese Welfare Ministry and adapted from Finningan et al. The score for severity of the syndrome peaked at 7 days of age and totalled 7 points, based on decreased muscle tone (1 point), tremor on stimulation (2 points), vomiting (2 points), and poor feeding (2 points). The severity decreased gradually, reaching a score of 0 by day 12 without any medication. The baby was fed a regular formula.

The patient’s platelet count initially fell to 117 × 10^9/l on day 6 but increased thereafter from 832 × 10^9/l on day 8 to a maximum of 1310 × 10^9/l on day 15. The result of a platelet adhesion test was 98.8% (normal range in our laboratory 20–60%) on day 15. Therefore, treatment with dipyridamole (2 mg/kg/day) was started on day 15 for prevention of thrombotic complications. A bone marrow aspirate on day 31 of age showed normal myeloid and erythroid precursors with an increased number of megakaryocytes: total cell count, 168 333/µl; megakaryocyte count, 198/µl (0.12%; the normal range is 79.9–269.8/µl); and serum thrombopoietin concentration was not increased (15.0 mU/ml). Blood thrombopoietin concentration, measured by a sensitive enzyme linked immunosorbent assay, and interleukin 6 (IL6) concentrations, measured by chemiluminescent enzyme immunoassay, were not elevated, but rather depressed; plasma thrombopoietin concentration ranged from 7 to 63.1 pg/ml (the normal range is 79.9–269.8 pg/ml at 1 month and 36.9–150.5 pg/ml at 2–11 months), and serum IL6 concentrations ranged from 0.3 to 5.2 pg/ml (the normal range is 2.4–10.5 pg/ml at day 5 and 0.7–11 pg/ml at day 40). Serum C reactive protein concentrations were < 0.1 mg/dl. After the platelet count decreased to 820 × 10^9/l on day 91, dipyridamole was stopped. Thereafter, the platelet count decreased further to 600 × 10^9/l. However, it remained relatively high, over 400 × 10^9/l after 4 months of age (fig 1). The infant had no symptoms attributable to thrombocytosis.
Neonatal thrombocytosis from maternal drug use during pregnancy

Thrombocytosis secondary to maternal drug use usually persists for about 16 weeks. In our case, a thrombocytosis of over $800 \times 10^9/l$ persisted for about three months, followed by relatively high platelet counts near the upper limit of normal thereafter.

Thrombopoietin is a glycoprotein that primarily regulates megakaryocyte development and platelet production. It is high during secondary thrombocytosis. In our case, the plasma thrombopoietin concentrations were persistently low during the thrombocytosis, in contrast with those reported in secondary thrombocytosis. However, the report of increased thrombopoietin concentrations preceding thrombocytosis in an inflammatory disorder, Kawasaki disease, suggests the possibility of increased thrombopoietin concentrations during the prenatal/perinatal period in our patient. Unfortunately, we did not measure plasma thrombopoietin concentrations before 2 weeks of age.

Cytokines other than thrombopoietin, such as IL1, IL-3, IL6, and IL11, stimulate platelet production in vivo. In secondary thrombocytosis of various causes, serum IL6 and C reactive protein concentrations are often significantly increased. In our case, we found a relatively low plasma IL6 concentration and negative C reactive protein, suggesting that they were not involved in this patient’s thrombocytosis. Similarly, serum erythropoietin concentration, which is usually high in iron deficiency anaemia and may contribute to thrombocytosis during human recombinant erythropoietin treatment for anaemia of prematurity, was not elevated in our patient.

Which of the five drugs prescribed for the mother was the cause of our patient’s thrombocytosis? In the report of Burstein et al on thrombocytosis in newborn infants of mothers using methadone plus other drugs, all but two mothers used other drugs (diazepam, cocaine, heroin, morphine, amphetamine, and pheno-barbital). However, a report on accidental overdosage of haloperidol was interesting because some children who were given the drug accidentally developed transient thrombocytosis. Apart from this, there are no clues about which of the five drugs were responsible for the thrombocytosis.

Discussion

In the neonatal period, essential thrombocytosis is extremely rare, and most high platelet counts in childhood are the result of secondary thrombocytosis. Maternal drug abuse has been reported to be one cause of secondary thrombocytosis in infants. The drugs in these cases were mostly narcotics.

Thrombocytosis has been reported to occur in the offspring of female mice receiving DL-methadone, whereas it has not been documented in adult mice or adult humans following the withdrawal of methadone. Interestingly, transient thrombocytosis occurred in five of 24 children who were given an accidental overdose of haloperidol. This occurred 16 days after the final dose of haloperidol. We speculate that thrombocytosis may occur only in infants and/or children about two weeks after their last exposure to some drugs such as narcotic or psychopharmaceutical drugs, although the detailed mechanism is not known.

Thrombocytosis secondary to maternal drug use usually persists for about 16 weeks. In our case, a thrombocytosis of over $800 \times 10^9/l$ persisted for about three months, followed by relatively high platelet counts near the upper limit of normal thereafter.

Thrombopoietin is a glycoprotein that primarily regulates megakaryocyte development and platelet production. It is high during secondary thrombocytosis. In our case, the plasma thrombopoietin concentrations were persistently low during the thrombocytosis, in contrast with those reported in secondary thrombocytosis. However, the report of increased thrombopoietin concentrations preceding thrombocytosis in an inflammatory disorder, Kawasaki disease, suggests the possibility of increased thrombopoietin concentrations during the prenatal/perinatal period in our patient. Unfortunately, we did not measure plasma thrombopoietin concentrations before 2 weeks of age.

Cytokines other than thrombopoietin, such as IL1, IL-3, IL6, and IL11, stimulate platelet production in vivo. In secondary thrombocytosis of various causes, serum IL6 and C reactive protein concentrations are often significantly increased. In our case, we found a relatively low plasma IL6 concentration and negative C reactive protein, suggesting that they were not involved in this patient’s thrombocytosis. Similarly, serum erythropoietin concentration, which is usually high in iron deficiency anaemia and may contribute to thrombocytosis during human recombinant erythropoietin treatment for anaemia of prematurity, was not elevated in our patient.

Which of the five drugs prescribed for the mother was the cause of our patient’s thrombocytosis? In the report of Burstein et al on thrombocytosis in newborn infants of mothers using methadone plus other drugs, all but two mothers used other drugs (diazepam, cocaine, heroin, morphine, amphetamine, and pheno-barbital). However, a report on accidental overdosage of haloperidol was interesting because some children who were given the drug accidentally developed transient thrombocytosis. Apart from this, there are no clues about which of the five drugs were responsible for the thrombocytosis.

Rapid responses

Letters on the following papers have been published recently as rapid responses on the ADC website. To read these letters visit [www.archdischild.com](http://www.archdischild.com) and click on “read rapid responses”:

**Dexamethasone treatment and cerebral palsy.** P O D Pharao. *Arch Dis Child Fetal Neonatal Ed* 2001;84:140.


If you would like to post an electronic response to these or any other articles published in the journal, please go to the website, access the article in which you are interested, and click on “eLetters: Submit a response to this article” in the box in the top right hand corner.